Our Product Portfolio

Subcutaneous injection is a highly effective route to administer various drug types including small molecules and biologic drugs.
Our parenteral device range is used to treat patients with hormonal disorders such as diabetes and infertility. Besides, patients with other chronic conditions such as immune disorders could also benefit safety coupled with an enhanced injection experience from using our devices.

Intranasal delivery is a common route of administration for treating various indications, from allergic rhinitis to breakthrough cancer pain (fast-acting pain control by nasal spray).
Nasal delivery is an attractive option for locally acting medications (e.g. saline solutions, decongestants, corticosteroids or antihistamines) which treat allergic rhinitis and nasal congestion.
More drugs targeting other therapeutic fields and diseases may join the increasing ranks of marketed products for systemic delivery using the nasal route, which may vary from benign to serious health condition.

Nemera designs and develops 2 types of inhalers, Pressurized Metered Dose Inhalers and Dry Powder Inhalers, to treat the following diseases:

• Asthma is a chronic inflammatory disease is a chronic disease of the air passages of the lungs which causes recurring symptoms, such as reversible airflow obstruction, episodes of wheezing, coughing, chest tightness, and shortness of breath. It was estimated that more than 339 million people had Asthma globally in 2016. There is no cure for asthma, but symptoms can be prevented by using of inhaled corticosteroids.
• COPD (Chronic obstructive pulmonary disease) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year). COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids.

Our systems aim to be used for all diseases for which the treatments can be administered via the skin:

• Hormonal disorders (hypogonadisms or menopausal symptoms)
• Psoriasis, an autoimmune disease that causes inflammation in the body, consisting of red, scaly plaques occurring most commonly on the elbows, knees, scalp, and lower back, but any skin surface can be involved. Psoriasis is estimated to affect 2–4% of the population of the western world.
• Eczema, a common chronic or recurrent inflammatory skin disease characterized by acute flare-ups of eczematous pruritic lesions over dry skin. It affects 15-20% of children and 1-3% of adults worldwide.
• Acne, a common chronic skin disease involving blackheads or whiteheads, pimples, oily skin, and possible scarring. Acne is estimated to affect 9.4% of the global population, making it the eighth-most prevalent disease worldwide.
• Hair loss.
• Topical pain, like painful muscles or joints.

Given most of these treatments are self-administered by the patient, convenience such as 360-degree usage and safety are important criteria to increase compliance rates.